Mitigare® (Colchicine) 0.6 mg Capsules and Authorized Generic Colchicine 0.6 mg Capsules

It’s easy to see why more gout patients are turning to Mitigare® (colchicine)

Effective, Affordable and
Accessible Gout Flare Prevention

Mitigare® (Colchicine) Gout Flare Prevention is Care that Comes in a CapsuleAnd, care that comes in a capsule. Hikma’s Mitigare® (Colchicine) 0.6 mg Capsules and its Authorized Generic Colchicine 0.6 mg Capsules reduce the frequency and severity of gout flares in a statistically significant percentage of patients1,2,3 and represent affordable options for gout flare prevention in appropriate adult patients4.

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis has not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

True Blue Savings Card Available

Use the True Blue Savings Card and you can receive Authorized Generic Colchicine 0.6 mg Capsules or Mitigare® (Colchicine) 0.6 mg Capsules. 

Pay as little as

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 and refills are as little as $5. Maximum savings of $65 on first fill, $50 on refills. Must meet eligibility requirements. See complete Terms & Conditions and eligibility requirements. 

 

DOWNLOAD YOUR CARD NOW

 

Who is Affected by Gout?

Although gout affects more men than women, millions are impacted by the disease.5

From the Gout Prevention Blog

Fast Facts on the Mitigare® (Colchicine) True Blue Savings Card

The Mitigare® True Blue Savings Card helps qualified patients save on their colchicine therapy. With the Mitigare® True Blue Savings Card, eligible patients can receive Mitigare®(colchicine) 0.6 mg Capsules or Authorized Read more...

From the Gout Prevention Blog

Gout Awareness Day 2023

Wear Blue for Gout! Gout Awareness Day, held every year on May 22, is more than just a good reason to wear blue—it’s a great opportunity to educate others about Read more...

References

  1. Mitigare® (colchicine) capsules [prescribing information]. Columbus, OH: West-Ward Columbus Inc.; 2019.
  2. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 Dec;31(12):2429-2432.
  3. Yu et al. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179-192.
  4. First Databank. AnalySource®website. Available at: https://www.analysource.com/. Accessed February 14, 2019.
  5. Chen-Xu M, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019 June;71(6):991-999.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.